These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31764258)

  • 21. Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment.
    Quaife M; Eakle R; Cabrera M; Vickerman P; Tsepe M; Cianci F; Delany-Moretlwe S; Terris-Prestholt F
    BMJ Open; 2016 Jun; 6(6):e010682. PubMed ID: 27354071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "We are not the same": African women's view of multipurpose prevention products in the TRIO clinical study.
    Shapley-Quinn MK; Manenzhe KN; Agot K; Minnis AM; van der Straten A
    Int J Womens Health; 2019; 11():97-107. PubMed ID: 30799959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV prevention is not all about HIV - using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection.
    Vickerman P; Quaife M; Kilbourne-Brook M; Mvundura M; Eakle R; Terris-Prestholt F
    BMC Infect Dis; 2020 Sep; 20(1):704. PubMed ID: 32977745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study.
    van der Straten A; Ryan JH; Reddy K; Etima J; Taulo F; Mutero P; Taylor J; Piper J; Musara P;
    J Int AIDS Soc; 2020 Jun; 23(6):e25536. PubMed ID: 32524700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
    Tolley EE; Li S; Zangeneh SZ; Atujuna M; Musara P; Justman J; Pathak S; Bekker LG; Swaminathan S; Stanton J; Farrior J; Sista N
    J Int AIDS Soc; 2019 Oct; 22(10):e25408. PubMed ID: 31651098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
    Govender EM; Mansoor LE; Abdool Karim Q
    AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.
    Montgomery ET; Atujuna M; Krogstad E; Hartmann M; Ndwayana S; OʼRourke S; Bekker LG; van der Straten A; Minnis AM
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):542-550. PubMed ID: 30865050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
    Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
    AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
    Guthrie KM; Rosen RK; Vargas SE; Getz ML; Dawson L; Guillen M; Ramirez JJ; Baum MM; Vincent KL
    PLoS One; 2018; 13(5):e0197269. PubMed ID: 29758049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe.
    Duby Z; Katz AWK; Browne EN; Mutero P; Etima J; Zimba CC; Woeber K; Atujuna M; Reddy K; van der Straten A;
    AIDS Behav; 2020 Feb; 24(2):617-628. PubMed ID: 31030301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of end-user research to inform future multipurpose prevention technologies in sub-Saharan Africa: a scoping review.
    Bhushan NL; Ridgeway K; Luecke EH; Palanee-Phillips T; Montgomery ET; Minnis AM
    Front Reprod Health; 2023; 5():1156864. PubMed ID: 37325244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incorporating end-users' voices into the development of an implant for HIV prevention: a discrete choice experiment in South Africa and Zimbabwe.
    Browne EN; Manenzhe K; Makoni W; Nkomo S; Mahaka I; Ahmed K; Shapley-Quinn MK; Marton T; Luecke E; Johnson L; van der Straten A; Minnis AM
    BMC Womens Health; 2023 Feb; 23(1):58. PubMed ID: 36765358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
    Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
    Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on biomedical HIV prevention options among women who inject drugs in Kenya.
    Bazzi AR; Yotebieng KA; Agot K; Rota G; Syvertsen JL
    AIDS Care; 2018 Mar; 30(3):343-346. PubMed ID: 28780885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose).
    Gill K; Happel AU; Pidwell T; Mendelsohn A; Duyver M; Johnson L; Meyer L; Slack C; Strode A; Mendel E; Fynn L; Wallace M; Spiegel H; Jaspan H; Passmore JA; Hosek S; Smit D; Rinehart A; Bekker LG
    J Int AIDS Soc; 2020 Oct; 23(10):e25626. PubMed ID: 33034421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.
    Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P
    J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative Findings on MPT Attribute Preferences from the CUPID Study (MTN-045).
    Bhushan NL; Musara P; Hartmann M; Stoner MCD; Shah SR; Nabukeera J; Rukundo I; Mutero P; Lewis MA; Piper J; Shapley-Quinn MK; Etima J; Minnis AM
    J Int AIDS Soc; 2022 Oct; 25(10):e26024. PubMed ID: 36254362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding women and men's acceptability of current and new HIV prevention technologies in KwaZulu-Natal, South Africa.
    Govender E; Abdool Karim Q
    AIDS Care; 2018 Oct; 30(10):1311-1314. PubMed ID: 29914270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation strategies for integrating pre-exposure prophylaxis for HIV prevention and family planning services for adolescent girls and young women in Kenya: a qualitative study.
    Roche SD; Barnabee G; Omollo V; Mogaka F; Odoyo J; Bukusi EA; Morton JF; Johnson R; Celum C; Baeten JM; O'Malley G
    BMC Health Serv Res; 2022 Mar; 22(1):422. PubMed ID: 35354456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
    Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
    AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.